MODAG GmbH is the winner of the PEP Award 2014 in the category „Early stage start-up projects“. The PEP Promotor-program of the Federal Ministry of Education and Research is awarding the innovative start-up team for the development of a drug candidate for the treatment of neurodegenerative diseases.
On 30. September 2014 Prof. Dr. Armin Giese from the Ludwig-Maximilians-Universität München received the award in Bonn, representing the start-up team. The team also comprises Prof. Dr. Christian Griesinger from the Max Planck Institute for Biophysical Chemistry in Göttingen, Dr. Markus Kostka und Dr. Torsten Matthias. The young company´s aim is to develop a drug candidate, which significantly reduces the deposition of disease-relevant accumulations of protein in the brain, which play an important role in the pathogenesis of many neurodegenerative diseases. The active substance „anle138b“ is now to be developed up to market maturity to significantly reduce the effects of diseases such as Parkinson’s, Alzheimer’s and Creutzfeld-Jakob in the future.
“We are very happy about the prize, which underlines the outstanding potential of our technology”, says Armin Giese. “Moreover we thank the technology transfer offices Bayerische Patentallianz GmbH and Max Planck Innovation for their start-up support and the search for financing”.